1. In vitro activity of Ceftazidime–Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.
- Author
-
Bakthavatchalam, Yamuna Devi, Routray, Abhisek, Mane, Akshata, Kamat, Shweta, Gupta, Anu, Bari, Anurag Kumar, Rohit, Anusha, Poojary, Aruna, Mukherjee, Dip Narayan, Sethuraman, Nandini, Munshi, Nita, Shah, Sweta, Balaji, Veeraraghavan, and Gupta, Yogesh
- Subjects
- *
ESCHERICHIA coli , *COMPARATOR circuits , *MULTIDRUG resistance , *KLEBSIELLA pneumoniae - Abstract
ATLAS (Antimicrobial Testing Leadership and Surveillance) detects trends in multi-drug resistance longitudinally over time. In the present study, the in vitro activity of ceftazidime-avibactam and comparators was analyzed against Escherichia coli (n = 458) and Klebsiella pneumoniae (n = 455) isolates obtained from 9 centers across India. The overall susceptibility to ceftazidime-avibactam was observed to be 72% among K. pneumoniae isolates and 87% among E. coli isolates. Among the tested carbapenem resistant isolates, 51% of CR- K. pneumoniae and 24% of CR- E. coli were susceptible to ceftazidime- avibactam. OXA-48 like was identified in 52% of the K. pneumoniae isolates followed by co-production of NDM with OXA-48 like in 27%. NDM was predominantly identified in 68% of the E. coli isolates followed by OXA-48 like in 24% isolates. The findings suggest that ceftazidime- avibactam is a reasonable alternative to standard therapy for management of carbapenem resistant Enterobacterales infections particularly with K. pneumoniae and E. coli with the OXA-48 like genotype. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF